IRLAB presents application of deep learning on multidimensional CNS drug efficacy data

January 12, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) presents results from a collaboration between the Department of Mathematical Sciences at Chalmers University of Technology, Gothenburg, the specialist artificial intelligence (AI) company Smartr and IRLAB. Based on multidimensional in vivo phenotypic dose response profiles generated by IRLAB’s ISP technology, it is found that in particular multilayer perceptron networks perform well for prediction of therapeutic indication and classification of drug candidates. The methodology further holds promise to discover new or expanded indications for both drug candidates and approved treatments within the central nervous system (CNS).

Read More >

IRLAB presents new data indicating that mesdopetam could prevent dyskinesia in Parkinson’s Disease

January 11, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) has obtained new results from preclinical studies which indicate that the drug candidate mesdopetam also has the potential to prevent the development of levodopa-induced dyskinesias, involuntary and troublesome movements, in Parkinson’s Disease. This increases the commercial potential for mesdopetam. The compound has previously been shown efficacious in the treatment of already established dyskinesia, which is further studied in an ongoing Phase IIb/III study. The results will be presented at the Society for Neuroscience (SfN) Global Connectome: A Virtual Event on January 11, 2021.

Read More >

Interview with CEO and CFO around the recent right issue (Swedish)

December 21, 2020 Read More >

IR contact

Viktor Siewertz, CFO
+46(0)72 710 70 70